Thymosin alpha-1 (Tα1, sold pharmaceutically as Zadaxin or thymalfasin) is a peptide your thymus naturally makes. Its job is to train and coordinate T cells, NK cells, and dendritic cells, the parts of the immune system that recognise and clear viruses, bacteria, fungi, and abnormal cells. People take it when their immune system is underperforming: chronic viral infection (it's an approved hepatitis B drug in 35+ countries), repeated infections that won't clear, immune recovery after serious illness, post-chemo or post-COVID lymphopenia, and increasingly as an immune adjunct in cancer care. It also gets used by older adults trying to push back on age-related immune decline, because the thymus shrinks with age and endogenous Tα1 levels fall with it.
The practical point that makes Tα1 unusual among research peptides: it's one of the most clinically tested peptides in existence, with over 11,000 patients enrolled in more than 30 trials. The downside is that the evidence is uneven. It works well for some indications (chronic hepatitis B, vaccine response in immunocompromised patients) and is genuinely uncertain or negative for others (the largest sepsis trial was null overall). Worth knowing what bucket you're actually in before running it.
A naming note before you go shopping. Thymosin alpha-1 is completely different from TB-500 (Thymosin Beta-4). They share a name because both were originally isolated from the same crude thymus extract (thymosin fraction 5) in the 1970s, but Tα1 is an immune-modulating peptide and Tβ4 is a tissue-repair peptide. Different molecules, different sequences, different uses. Vendors sometimes mix them up. Check the sequence on the COA.
Deep-dive
Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from calf thymus by Allan Goldstein and colleagues at the Albert Einstein College of Medicine in 1972, then chemically characterised and synthesised in 1977. Its synthetic form, thymalfasin, is identical to the human peptide and is what's used in every clinical trial and every pharmaceutical preparation. Endogenous Tα1 is produced primarily by thymic epithelial cells and circulates throughout the body, where it acts on immune cells in the bloodstream and tissues.
How it actually works. Tα1 is best described as a master regulator rather than a one-way stimulant. It binds to Toll-like receptors, primarily TLR2 and TLR9, on dendritic cells and monocytes, which sit at the interface between innate and adaptive immunity. When Tα1 binds these receptors, dendritic cells mature and start presenting antigens more effectively to T cells. The downstream effects: more naive T cells maturing into functional Th1 helper cells, more IL-2 and interferon-gamma being produced, higher NK cell cytotoxicity, and reversal of T-cell exhaustion in settings where the immune system has been chronically overworked.
The twist is that Tα1 also expands regulatory T cells and dampens excessive inflammation in cytokine storm conditions. So in a depleted or exhausted immune system it acts like a stimulant, restoring T-cell function and antiviral activity. In an over-activated system, like severe sepsis or COVID cytokine storm, it pulls inflammation back toward baseline. This bidirectional behaviour is why the literature describes it as an immune "modulator" rather than a stimulant, and is the mechanistic rationale for trying it in both immunodeficiency and hyperinflammation.
Pharmacokinetics are short and unremarkable. After subcutaneous injection, plasma levels peak around 1-2 hours with a serum half-life of about 2 hours. After a single 1.6 mg dose, circulating Tα1 increases roughly 50-100x baseline. The peptide itself clears quickly, but the downstream immune effects (changes in T-cell populations, antibody responses, cytokine profiles) persist for days to weeks.
Chronic hepatitis B, the strongest indication. This is what got Tα1 approved as a drug. Multiple Phase 3 trials in the 1990s and 2000s tested 1.6 mg subcutaneously twice weekly for 6-12 months in chronic HBV patients. A pooled analysis of three randomised trials in 223 patients showed Tα1 monotherapy roughly doubled the rate of sustained virological response compared to placebo at 12 months post-treatment, a slow but real effect that builds over months. A larger RCT comparing 26-week, 52-week, and observation arms found complete virological response at 18 months in 40.6% of the 26-week group versus 9.4% of controls. The effect is not interferon-like fast viral clearance, it's a slower restoration of immune competence that lets the body do the clearing.
Vaccine adjuvant in immunocompromised patients. Older adults and patients on dialysis often fail to mount a protective antibody response to standard vaccines. Tα1 partially restores this. McConnell et al. in 1989 gave 90 elderly subjects Tα1 alongside trivalent influenza vaccine and reported substantially improved antibody titres. Carraro et al. in 2012 showed that 3.2-6.4 mg Tα1 enhanced seroconversion to pandemic H1N1 vaccine in haemodialysis patients, with the combination meeting regulatory licensing criteria by day 21 while vaccine alone did not. In hepatitis B vaccine non-responders on dialysis, adding Tα1 lifted seroconversion from around 17% to 64%. This is the cleanest non-HBV indication.
Sepsis, where the picture got complicated. Early trials looked promising. The ETASS trial in 2013 randomised severe sepsis patients to standard care plus Tα1 or standard care alone and found lower 28-day mortality in the Tα1 arm. A 2016 systematic review of 10 RCTs in 530 patients pooled a 41% reduction in 28-day mortality. The largest trial to date, the TESTS phase 3 trial published in BMJ in 2025, enrolled 1106 adults with sepsis across 22 centres in China and found no difference in 28-day mortality (23.4% Tα1 vs 24.1% placebo). Subgroup analyses suggested possible benefit in older patients (over 60) and those with diabetes, and harm in patients under 60. The most recent 2025 meta-analysis including TESTS still shows pooled mortality reduction, but the high-quality studies on their own no longer reach significance. The reasonable read is that Tα1 probably helps a specific subset of older or immunocompromised sepsis patients, and doesn't help unselected ICU populations.
COVID-19. Tα1 was widely used in China during the pandemic. The Liu et al. retrospective study of 76 severe cases reported that Tα1 reduced mortality, restored T-cell counts in lymphopenic patients, and reversed T-cell exhaustion. Mechanistic work in PBMCs and single-cell RNA sequencing studies confirmed that Tα1 mitigates cytokine signalling in CD8+ T cells from COVID patients and restores thymic output as measured by TREC levels. Other studies, including a 334-patient trial in Shanghai, found no benefit on lymphocyte recovery or viral clearance. The retrospective design of the positive studies and contradictory results from later trials mean the COVID story is suggestive but not settled.
Cancer, mostly as an adjunct. Tα1 has been studied in melanoma, hepatocellular carcinoma, and non-small cell lung cancer, generally in combination with chemotherapy, interferon, or checkpoint inhibitors. The Phase 2 Maio et al. melanoma trial in 488 stage IV patients showed acceptable safety and a survival signal when combined with dacarbazine and interferon. Long-term follow-up suggested patients who received Tα1 before later checkpoint inhibitor therapy had better outcomes than those who didn't. In resectable NSCLC and hepatocellular carcinoma, adjuvant Tα1 has shown overall survival benefits in several Chinese trials, particularly in HBV-related liver cancer. None of this is FDA-approved use, but the mechanism (driving "cold" tumours "hot" via dendritic cell activation, potentially synergising with anti-PD-1) is biologically coherent.
Chronic fatigue, Lyme, and persistent post-viral states. This is where most of the recreational and integrative-medicine use happens, and where the evidence is thinnest. Mechanistically the rationale is reasonable: many post-infectious fatigue syndromes show T-cell exhaustion, reduced NK cell activity, and a Th2-skewed cytokine profile, exactly the pattern Tα1 is meant to reverse. There are small case series and clinical reports describing reduced fatigue, improved cognition, and better infection-fighting capacity over 8-12 weeks of treatment, but no controlled trial in ME/CFS or post-treatment Lyme syndrome has been published. User reports are mixed: some describe clear improvements in energy and post-exertional malaise within 4-8 weeks, others report worsening of symptoms in the first few weeks (possibly an immune-flare reaction), and others notice nothing. If you're in this category, you're running an n=1 experiment.
HIV and immune reconstitution. A 12-week pilot in HIV patients with low CD4 counts on HAART showed Tα1 was well tolerated and increased TREC levels (a marker of new T-cell output from the thymus), though CD4 counts didn't change significantly over the short trial period. The relevance for the modern HIV population, where viral suppression is routine, is mainly in patients with persistent low CD4 counts despite undetectable viral load.
Women. Most of the Tα1 trial literature has included both sexes, with no major sex-specific safety issues reported. There are real biological reasons to think women may respond differently though, and they're worth knowing. First, healthy women have lower baseline serum Tα1 than healthy men in cohort studies, which on its own doesn't tell you they need more, but is consistent with women's broader pattern of more reactive immune systems and higher autoimmune disease risk. Second, the female thymus and its output of T cells are regulated by oestrogen and progesterone and shift across the menstrual cycle, pregnancy, and menopause, so baseline thymic function is more dynamic in women. Third, women mount stronger antibody responses to most vaccines than men do, meaning the headroom for a vaccine adjuvant like Tα1 may be smaller in younger pre-menopausal women and more meaningful postmenopausally. Fourth, a retrospective gender analysis in COVID-19 patients found different cytokine response patterns to Tα1 in men and women, with men showing higher post-treatment CRP and IL-6 than women, suggesting the same dose produces different downstream immune signatures by sex. None of this changes the dose, but it argues for paying more attention to the response over the first 4-8 weeks rather than assuming the male-derived dosing schedule is optimal. Skip in pregnancy and breastfeeding, no safety data.
What the evidence does not support. Tα1 is sometimes marketed as a general anti-aging, longevity, or wellness peptide for healthy adults with no specific immune problem. The mechanistic argument (thymus shrinks with age, endogenous Tα1 declines, so supplementing should help) is real but unproven in healthy populations. Every well-controlled study has been in a disease state. There is no published trial showing that a healthy 35-year-old with a normal immune system benefits from regular Tα1 cycles. The honest answer is that if your immune system is working, you have little to gain.
Dosage:
- Standard pharmaceutical dose: 1.6 mg subcutaneously twice weekly, with injections spaced 3-4 days apart (e.g., Monday and Thursday). This is the dose used in essentially every Phase 3 trial and the dose Zadaxin is licensed at. Adults under 40 kg use 40 mcg/kg twice weekly.
- Cycle length: 6 months for hepatitis B per label, 8-12 weeks is the most common community protocol for general immune support, chronic infection support, or post-viral recovery. Effects build slowly, so judging at 4 weeks is too early.
- Sepsis or acute immunosuppression context: clinical trials used much shorter, more intensive dosing, every 12 hours for 7 days. This is an inpatient ICU dose and not relevant for self-administered use.
- Cancer adjuvant dosing in trials has ranged from 1.6 mg twice weekly to 3.2 mg daily over chemotherapy cycles. This is an oncology-clinician decision, not a self-administered protocol.
- Vaccine adjuvant protocols in older adults have used 0.9 mg/m² (roughly 1.6 mg) twice weekly for 4-8 weeks around the vaccination date, with injections beginning 1-2 weeks before the vaccine.
- Reconstitution and storage: A 5 mg vial reconstituted with 1 mL bacteriostatic water gives 5 mg/mL, so 1.6 mg = 0.32 mL or 32 units on a U-100 insulin syringe. Refrigerated post-reconstitution and stable for about 2-7 days at 4°C per FDA pharmacology data, longer if frozen. Lyophilised powder should be stored desiccated below -18°C for long-term stability.
- Injection site: subcutaneous into abdomen, thigh, or upper arm. Rotate sites. Insulin syringe with a short needle is fine.
- Stacking: has been combined with interferon, antivirals, chemotherapy, and checkpoint inhibitors in clinical trials with no significant interactions reported. No documented interactions with common supplements. Stacking with TB-500 (Thymosin Beta-4) targets different goals (Tα1 immune, Tβ4 tissue repair) and the two are not redundant. No female-specific dose adjustment.
Here's what you can expect:
Nothing acute. Tα1 doesn't produce a noticeable subjective effect within hours or days of injection. The immune system rebuilds slowly.
In the first 2-3 weeks, most people notice nothing, or some report a mild flu-like feeling for a few days at the start of a cycle (low-grade fever, mild fatigue, slight aches), which is consistent with immune activation and resolves on its own. A subset of people, particularly those with chronic post-infectious states or autoimmune-flavoured fatigue, report a transient worsening of symptoms in the first 2-4 weeks before things improve.
From week 4-8, in the context of an actual immune problem (chronic infection that won't clear, post-viral fatigue, frequent illness, immune recovery after chemo or major surgery), people typically describe getting sick less often or recovering faster from infections they do get, more steady energy, and fewer of the low-grade infection-prone feelings that often hang on after a bad acute illness.
By weeks 8-12, the effect tends to be most evident in the things you don't notice: not getting the cold that's going round, faster recovery from infections, better tolerance of training and stress. People running it for chronic hepatitis B or as a cancer adjunct won't notice anything subjectively at all, the effect is on viral load, T-cell counts, or oncology outcomes, not how they feel.
In the wrong context (healthy adult, normal immune system, no specific complaint), most people report no concrete effect across an entire cycle. Tα1 has very little to do unless the system is under load.
Side effects & risks:
- Excellent safety profile across decades of clinical use. Pooled data from over 600,000 treated patients post-marketing and 11,000+ in clinical trials shows adverse event rates comparable to placebo in most studies. No hepatotoxicity, no renal toxicity, no hormonal suppression, no detectable carcinogenicity signal.
- Injection site reactions are the most common side effect: mild redness, soreness, occasional bruising. Rotating sites and using fresh needles minimises this.
- Transient flu-like symptoms during the first 1-2 weeks of a cycle, in some users. Low-grade fever, mild fatigue, muscle aches. Consistent with immune activation, not a true adverse drug reaction. Resolves without intervention.
- ALT flare in chronic hepatitis B treatment is documented and expected, a transient rise to more than twice baseline can occur as the immune system starts clearing infected hepatocytes. Per the Zadaxin label, treatment is generally continued through this unless signs of liver failure appear. If you're using it for hepatitis B, you need monitoring.
- Autoimmune disease, use with caution. Tα1 enhances T-cell function and Th1 cytokines, which is the exact axis driving most autoimmune conditions. There is observational data showing higher endogenous Tα1 in psoriatic arthritis, rheumatoid arthritis, and lupus compared to healthy controls, though the direction of cause is unclear. Reasonable caution: not first-line in active autoimmune flare, and worth discussing with a clinician if you have known autoimmune disease.
- Solid organ transplant, avoid. Tα1 enhances immune surveillance, the opposite of what transplant patients on immunosuppression need. Theoretical rejection risk.
- Sepsis subgroup signal. The TESTS trial found a possible signal of harm in sepsis patients under 60. This doesn't translate cleanly to outpatient use, but it's a reminder that immune modulators are not universally pro-survival.
- Pregnancy and breastfeeding, avoid. No safety data and immune modulation during pregnancy is high-risk territory.
- Drug interactions are minimal. No interactions with common antivirals, antibiotics, statins, antihypertensives, or thyroid medications have been reported. Vaccines work better with it, not worse.
- Source quality matters. Like all peptides outside pharmaceutical channels, the grey market includes underdosed, contaminated, and outright fake product. Pharmaceutical Zadaxin from a licensed pharmacy is the gold standard. Compounded Tα1 from a reputable 503A compounding pharmacy is the next step down. Research-grade product from online vendors is the most uncertain, look for third-party Certificate of Analysis confirming sequence (28 amino acids, N-acetyl-serine at position 1) and purity above 98% before injecting anything.
Blood markers
Full blood count with lymphocyte differential, baseline and at 8-12 weeks. The most relevant marker if you're running Tα1 for immune support is CD4 and CD8 T-cell counts and the CD4/CD8 ratio, which trend up in people who respond. If you can't get T-cell subsets, total lymphocyte count is a reasonable proxy.
hs-CRP, baseline and at 8-12 weeks. Tα1 tends to normalise inflammation, pulling elevated CRP down in chronic inflammatory states and leaving it stable in healthy adults.
Liver enzymes (ALT, AST), baseline and monthly if running it for hepatitis B (an ALT flare is expected and clinically meaningful). For general immune use, baseline is enough.
Hepatitis B and C serology, baseline if you don't already know your status, particularly if considering Tα1 for chronic fatigue or post-viral symptoms where undiagnosed chronic viral hepatitis is on the differential.
HbA1c or fasting glucose if you're over 60 or diabetic, since the TESTS sepsis subgroup data suggested differential effects by diabetes status. Not because Tα1 changes glucose, but because diabetes status appears to modulate response.
Cancer screening, age-appropriate. Before a first cycle, make sure you're up to date on age-appropriate screening. Unlike TB-500 (Thymosin Beta-4), Tα1 is not pro-angiogenic and the cancer data is largely favourable, but you don't want to be modulating immunity without knowing your baseline.
For most people running an 8-12 week cycle for general immune support or post-viral recovery, CBC with differential, hs-CRP, and a liver panel before and after is sufficient. T-cell subsets are the highest-yield extra test if you can get them.
Thymosin alpha-1 is approved as Zadaxin (thymalfasin) in over 35 countries for chronic hepatitis B and as an immune adjuvant. Not FDA-approved in the United States, and the FDA restricted compounding pharmacies from preparing it under the 503B bulks framework in 2023. Available internationally by prescription and in the US through some 503A compounding pharmacies and as a research peptide.